Featured Research

from universities, journals, and other organizations

Planned Safety Analysis Of A Breast Cancer Prevention Study Reveals Encouraging News For Exemestane

Date:
December 14, 2008
Source:
Georgetown University Medical Center
Summary:
An interim analysis of a breast cancer prevention study using exemestane finds an "acceptable" level of bone loss.

An interim analysis of a breast cancer prevention study using exemestane (Aromasinฎ) finds an "acceptable" level of bone loss.

The ongoing phase II study details reported today, by Jennifer Eng-Wong, MD, a breast cancer specialist at Georgetown's Lombardi Comprehensive Cancer Center at the San Antonio Breast Cancer Symposium, examines the use of exemestane in postmenopausal women who are at an increased risk of developing breast cancer based on commonly used risk assessment measures. In addition to exemestane, all the study participants received calcium carbonate and vitamin D.

Wong's report represents findings from a planned interim safety analysis in 18 women who completed one year of exemestane.

"We found a drop in bone mineral density in these women similar to what we've seen in women taking exemestane in the adjuvant treatment setting." Eng-Wong reports. "Like aromatase inhibitors in the adjuvant setting there is a small amount of bone loss in the spine and hip. The long term clinical impact of the small decrease is not known."

The exemestane study continues with endpoints including bone density measurements and change in breast density over two years of treatment. Dense breasts as observed on a mammogram are associated with an increase in a woman's risk of developing breast cancer.

In addition to Eng-Wong, other authors (all from the National Cancer Institute) include James C. Reynolds, David Venzon, Suparna Wedam, Sheila Prindiville, Jo Ann Zujewki, and Larissa Korde.

This study is funded by NCI Intramural Research Program and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center. The authors have no financial relationships to disclose.


Story Source:

The above story is based on materials provided by Georgetown University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Georgetown University Medical Center. "Planned Safety Analysis Of A Breast Cancer Prevention Study Reveals Encouraging News For Exemestane." ScienceDaily. ScienceDaily, 14 December 2008. <www.sciencedaily.com/releases/2008/12/081214090339.htm>.
Georgetown University Medical Center. (2008, December 14). Planned Safety Analysis Of A Breast Cancer Prevention Study Reveals Encouraging News For Exemestane. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/12/081214090339.htm
Georgetown University Medical Center. "Planned Safety Analysis Of A Breast Cancer Prevention Study Reveals Encouraging News For Exemestane." ScienceDaily. www.sciencedaily.com/releases/2008/12/081214090339.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins